PRTK Stock Overview Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Paratek Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Paratek Pharmaceuticals Historical stock prices Current Share Price US$2.23 52 Week High US$3.65 52 Week Low US$1.29 Beta 1.7 1 Month Change 2.29% 3 Month Change 0.91% 1 Year Change -2.62% 3 Year Change -60.95% 5 Year Change -77.01% Change since IPO -86.06%
Recent News & Updates Paratek Pharmaceuticals, Inc. Announces Board Changes Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index
CEO & Director recently sold US$108k worth of stock Aug 13
Consensus estimates of losses per share improve by 16% Aug 10
Forecast to breakeven in 2025 Aug 08
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 03 See more updates Paratek Pharmaceuticals, Inc. Announces Board Changes Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index
CEO & Director recently sold US$108k worth of stock Aug 13
Consensus estimates of losses per share improve by 16% Aug 10
Forecast to breakeven in 2025 Aug 08
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 03
Paratek Pharmaceuticals, Inc. Announces Modification of Barda Contract to Advance the Development of Nuzyra®? (Omadacycline) for Post-Exposure Prophylaxis (Pep) and Treatment of Pulmonary Anthrax Jul 11
No longer forecast to breakeven Jul 01
NexPoint Advisors Sends a Letter to Paratek Pharmaceuticals Jun 28
Paratek Pharmaceuticals, Inc. Presents New Data from NUZYRA®? (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023 Jun 13
Gurnet Point Capital Limited and Novo Holdings A/S entered into a definitive agreement to acquire Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK) for approximately $130 million. Jun 08
Gurnet Point Capital Limited and Novo Holdings A/S entered into a definitive agreement to acquire Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK) for approximately $130 million. Jun 07
Paratek Pharmaceuticals, Inc., Annual General Meeting, Jul 06, 2023 May 27
Paratek Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2023 May 12
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10
Price target decreased by 51% to US$6.67 May 10
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified Apr 17
Forecast breakeven date pushed back to 2024 Mar 17
Consensus estimates of losses per share improve by 10% Jan 26
Paratek Pharmaceuticals, Inc. Announces Inclusion of NUZYRA(R) (omadacycline) in China's National Reimbursement Drug List Jan 19
Paratek Pharmaceuticals, Inc. Appoints Jeffrey Stein as First Lead Independent Director Dec 21
Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA (omadacycline) under BARDA Project BioShield Dec 20
CEO & Director notifies of intention to sell stock Dec 19
Insufficient new directors Nov 16
Consensus revenue estimates fall by 11% Nov 10
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 05
Paratek Pharmaceuticals, Inc. Announces First Milestone Towards Creating A U.S. Manufacturing Supply Chain for Nuzyra® (Omadacycline) Under Barda Project Bioshield Contract Nov 01
Paratek Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 26
Paratek Pharmaceuticals: Patience Is Wearing Thin Aug 24
Consensus EPS estimates fall by 33% Aug 10
Forecast breakeven date pushed back to 2024 Aug 09
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 04
Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M Aug 03
Paratek Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 26
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from Russell 2000 Dynamic Index Jun 26
Consensus forecasts updated May 11
Price target decreased to US$21.00 May 07
Forecast breakeven date pushed back to 2024 May 07
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint May 06
Paratek Pharmaceuticals, Inc. Reiterates Guidance for the Year 2022 May 05
Insufficient new directors Apr 27
Paratek Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2022 Apr 23
Consensus EPS estimates fall by 19% Apr 12
Consensus revenue estimates fall by 10% Mar 21
Price target decreased to US$23.00 Mar 18
Forecast breakeven date pushed back to 2023 Mar 16 Paratek Pharmaceuticals, Inc. Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA in A Hollow Fiber System Model Against Pulmonary Mycobacterium Avium Complex Mar 10
Paratek Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 14, 2022 Mar 04
Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company Jan 03
President & Chief Commercial Officer notifies of intention to sell stock Dec 20
Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.46 loss in 3Q 2020) Nov 10
Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.46 loss in 3Q 2020) Nov 10
The Play On Paratek Pharmaceuticals Oct 18
Price target increased to US$25.67 Sep 30
Paratek Pharmaceuticals Presents New Data for NUZYRA® (omadacycline) at IDWeek 2021 Sep 24
Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria Aug 20
Consensus EPS estimates fall to -US$1.27 Aug 17
Second quarter 2021 earnings released: EPS US$0.21 (vs US$0.53 loss in 2Q 2020) Aug 11
Peeking Back In On Paratek Pharmaceuticals Aug 07
Paratek Pharmaceuticals, Inc. Announces First Barda Project Bioshield Procurement of Nuzyra Jun 30 Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from Russell 3000E Value Index
Paratek Pharmaceuticals, Inc. Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) with Nuzyra (Omadacycline) Jun 17
Price target decreased to US$16.00 Jun 17
Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial Jun 16
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Jun 02
Paratek shares rise after FDA approves NUZYRA oral only dosing regimen Jun 01
Forecast breakeven moved forward to 2022 May 21
First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.66 loss in 1Q 2020) May 19
Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business Apr 27
Full year 2020 earnings released: US$2.19 loss per share (vs US$3.93 loss in FY 2019) Mar 31
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic? Mar 01
Full year 2020 earnings released: US$2.19 loss per share (vs US$3.93 loss in FY 2019) Feb 26
Earnings beat expectations, revenue disappoints Feb 26
Paratek Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: US$7.57 Feb 05
Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful? Feb 01
Analysts lower revenue estimates to US$69.2m Jan 07
Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment Jan 04
New 90-day high: US$6.81 Dec 04
Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale Dec 01
Analysts increase EPS estimates to -US$1.34 Nov 13
Revenue beats expectations, earnings disappoint Nov 08
Third quarter 2020 earnings released: US$0.46 loss per share Nov 08
Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation Nov 06
CEO & Director exercised options to buy US$184k worth of stock. Nov 04
Paratek Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 28 Shareholder Returns PRTK US Pharmaceuticals US Market 7D 2.3% -2.0% -3.5% 1Y -2.6% 7.6% 22.1%
See full shareholder returns
Return vs Market: PRTK underperformed the US Market which returned 13.8% over the past year.
Price Volatility Is PRTK's price volatile compared to industry and market? PRTK volatility PRTK Average Weekly Movement 1.6% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: PRTK has not had significant price volatility in the past 3 months.
Volatility Over Time: PRTK's weekly volatility has decreased from 13% to 2% over the past year.
About the Company Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.
Show more Paratek Pharmaceuticals, Inc. Fundamentals Summary How do Paratek Pharmaceuticals's earnings and revenue compare to its market cap? PRTK fundamental statistics Market cap US$127.83m Earnings (TTM ) -US$62.73m Revenue (TTM ) US$177.00m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PRTK income statement (TTM ) Revenue US$177.00m Cost of Revenue US$64.13m Gross Profit US$112.87m Other Expenses US$175.60m Earnings -US$62.73m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -1.09 Gross Margin 63.77% Net Profit Margin -35.44% Debt/Equity Ratio -128.3%
How did PRTK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/09/22 06:31 End of Day Share Price 2023/09/20 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Paratek Pharmaceuticals, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Ulz Baird Jason Matthew Gerberry BofA Global Research Timothy Chiang BTIG
Show 9 more analysts 
